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Colorectal cancer (CRC) is the second most commonly diagnosed cancer in females and the third in males. More than 1.2 million 
cases around the globe are diagnosed every year and 
it is the estimated cause of death for more than half a 
million people each year. Metastatic CRC is the first 
presentation in approximately one-fourth of patients.1 
Another 30% of patients initially diagnosed with 
localised bowel cancer will subsequently develop liver 
metastases.1 The five-year survival rate for patients with 
stage IV CRC with liver metastases is approximately 
6%.2 However, if the liver is the only site involved and 
the metastases are amenable to surgical resection, then 
the five-year survival rate increases to 25–40%.2
The clinical evaluation of patients with CRC 
requires multiple imaging modalities such as computed 
tomography (CT), contrast-enhanced CT, magnetic 
resonance imaging (MRI), 18F-fluorodeoxyglucose 
(18F-FDG) positron emission tomography (PET) 
and PET/CT. All of these imaging modalities play 
a major role in the diagnosis and staging of CRC. In 
the February 2015 issue of SQUMJ, Jafferbhoy et al. 
retrospectively evaluated the value of 18F-FDG-PET/
CT imaging in the management of patients with 
metastatic CRC.3
18F-FDG-PET imaging has an important role 
in the diagnostic and staging algorithm. Current 
evidence-based indications for 18F-FDG-PET in the 
UK recommend the use of this imaging modality 
in the staging of patients with synchronous CRC 
and metastases at presentation, before considering 
surgical resection.4 This recommendation is similar to 
the North American National Comprehensive Cancer 
Network guidelines for the initial staging of CRC, 
which suggests the use of CT or MRI of the chest, 
abdomen and pelvis; 18F-FDG-PET/CT imaging should 
be reserved for situations in which curative resection is 
being considered.5 The incorporation of 18F-FDG-PET 
scanning can facilitate the detection of extrahepatic 
disease and, therefore, can reduce the need for non-
therapeutic laparotomies; however, we have to keep 
in mind that PET can be unreliable in certain settings 
where there is increased metabolic activity due to 
inflammation. In addition, mucinous adenocarcinomas 
may show a false-negative PET result.6,7
Wiering et al. performed a systematic review of 
data looking at the superiority of PET imaging over 
CT alone in the detection of extrahepatic disease.6 For 
hepatic disease or metastases, pooled sensitivity and 
specificity for PET was 80% and 92%, respectively, in 
comparison to 91% and 98% for extrahepatic disease 
or metastases.6 Corresponding values for CT imaging 
were 83% and 84% for hepatic metastases and 61% and 
91% for extrahepatic metastatic disease. The use of PET 
imaging led to a 25% change in clinical management.6
A randomised trial demonstrated that combining 
PET with triphasic CT imaging reduced the number 
of unnecessary laparotomies from 34 (45%) in the 
control group to 21 (28%) in the experimental group. 
This combination of PET and triphasic CT imaging 
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prevented unnecessary surgery in one of six patients, 
with a relative risk reduction of 38%.7
Similar findings were reported by Jafferbhoy et al.3 
18F-FDG-PET/CT imaging had a major impact on 
72.7% of patients in the preoperative group; the intent of 
treatment was changed from curative to palliative due to 
the presence of inoperable disease in 36.3%, resectable 
metastases were identified after indeterminate CT 
scanning in 27.3% and 9.1% avoided unnecessary 
surgery after negative 18F-FDG-PET/CT results.3
The previously reported benefit of PET in reducing 
unnecessary laparotomies was disputed by Moulton et 
al. in a recently published randomised trial in which 
404 patients with potentially resectable isolated 
colorectal liver metastases (CRLM) were randomly 
assigned to either undergo preoperative integrated 
PET/CT or forego PET/CT entirely.8 Only 8% of 
those who had undergone preoperative PET/CT had a 
change in surgical management. The frequency of liver 
resections were similar in both groups (91% versus 92% 
in the experimental and control groups, respectively). 
Additionally, there was no change in survival, with 
both groups demonstrating a two-year survival rate 
of 80%.8 Due to the differences in outcomes of these 
studies, more data are required to evaluate the impact 
of 18F-FDG- PET and PET/CT imaging on the clinical 
management of patients with CRLM.
Several studies have investigated the role of 18F- 
FDG-PET and PET/CT in patients with CRLM 
undergoing selective internal radiation therapy 
(SIRT) with yttrium-90 (90Y) microspheres.9–12 Radio-
embolisation using 90Y resin or glass microspheres, also 
known as a palliative treatment, reduces the mass of a 
liver tumour, eventually permitting surgical resection.13 
A recently published evidence-based review of the 
literature by Annunziata et al. included 19 studies 
looking at the role of 18F-FDG-PET and PET/CT 
in patients with CRLM undergoing SIRT with 90Y 
microspheres in 833 patients. The role of 18F-FDG-PET 
or PET/CT was evaluated in planning and assessing 
the response to treatment and evaluating PET as a 
prognostic tool.14
At present, the role of 18F-FDG-PET or PET/CT in 
planning SIRT for CRLM is still questionable. Different 
studies have revealed different outcomes and therefore 
no strong conclusion can yet be drawn.11,15,16 Further 
studies are needed to assess the role of 18F-FDG-PET 
or PET/CT in planning treatment before advising SIRT 
for patients with CRLM. A few recently published 
studies have investigated the role of 18F-FDG-PET or 
PET/CT imaging in the evaluation of patient response 
to SIRT.9,17,18 All these studies confirmed the usefulness 
of 18F-FDG-PET and PET/CT imaging.
Furthermore, the role of 18F-FDG-PET or PET/
CT as a prognostic tool has been evaluated by a few 
recently published studies.10,18–20 Gulec et al. looked at 
the relationship between functional tumour volume 
(FTV), total lesion glycolysis (TLG) and clinical 
outcomes. They demonstrated a correlation between 
semi-quantitative factors such as FTV and TLG with 
patient outcome and survival.19 Similarly, Fendler 
et al. reported the use of TLG in predicting survival 
in patients with CRLM; FTV and TLG were found 
to correlate with outcome and survival in these 
patients using the Response Evaluation Criteria In 
Solid Tumors.20 
Zerizer et al. investigated the role of early 18F-FDG-
PET/CT in predicting progression-free survival.18 
Early 18F-FDG-PET/CT was found to be superior 
to contrast-enhanced CT imaging in predicting 
progression-free survival in patients with CRLM 
treated with 90Y radioembolisation.18
18F-FDG-PET/CT is an emerging prognostic tool in 
patients with CRLM undergoing SIRT. However, this 
finding should be confirmed with larger prospective 
studies. Unfortunately, PET technology is currently 
not available in Oman at the present time and patients 
requiring PET scans are sent to nearby countries. With 
the establishment of an oncology service at the Sultan 
Qaboos University Hospital and an oncology centre at 
the Royal Hospital in Muscat, Oman, PET imaging is 
becoming a necessity. According to personal sources, 
a PET scanning facility will be installed this year. This 
will definitely improve the oncology services available 
in Oman and reduce the expenses required to send 
patients abroad.
In summary, the role of integrated PET/
CT imaging in selecting optimal CRLM surgical 
candidates and in the follow-up of surgical patients is 
uncertain. Until additional data are available, 18F-FDG-
PET scans are recommended for CRC staging and in 
selecting treatment options for patients, including the 
resection of metastases and SIRT. At present, limited 
evidence supports the use of 18F-FDG-PET/CT as a 
tool for planning SIRT, assessing treatment response 
and predicting progression-free survival.
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